Market Place
Sourcing Support
Revolution Medicines Reports Q3 2024 Financials & Progress
06 Nov 2024 //
GLOBENEWSWIRE
Revolution Medicine to Attend Upcoming Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Revolution to Report Financial Results for Q3 2024 Nov 6, 2024
30 Oct 2024 //
GLOBENEWSWIRE
Revolution Medicines Shares Data on RMC-9805 in PDAC Patients
25 Oct 2024 //
GLOBENEWSWIRE
Revolution Updates RMC-6236 Study in Advanced Pancreatic Cancer
23 Oct 2024 //
GLOBENEWSWIRE
Revolution Medicines Doses First Patient In Phase 3 Study Of RMC-6236
21 Oct 2024 //
GLOBENEWSWIRE
Revolution Medicines To Present At 2024 AACR-NCI-EORTC Symposium
07 Oct 2024 //
GLOBENEWSWIRE
Revolution Medicines Reports Q2 2024 Results And Corporate Progress
07 Aug 2024 //
GLOBENEWSWIRE
Revolution Medicines To Report Q2 2024 Results On August 7
31 Jul 2024 //
GLOBENEWSWIRE
Revolution Medicines Publishes Data On RAS(ON) Inhibitors In NSCLC Models
11 Jul 2024 //
GLOBENEWSWIRE
Revolution Medicines To Update On RMC-6236 Clinical Program
08 Jul 2024 //
GLOBENEWSWIRE
Revolution Medicines: Participating At Goldman Sachs Conference
05 Jun 2024 //
GLOBENEWSWIRE
Revolution Medicines Q1 2024 Results, Progress Update
08 May 2024 //
GLOBENEWSWIRE
Revolution Medicines Q1 2024 Results On May 8 After Market Close
01 May 2024 //
GLOBENEWSWIRE
Revolution Med on RMC-6236 Discovery & Research to inhibits RAS(ON) Proteins
09 Apr 2024 //
GLOBENEWSWIRE
Revolution Announces Publications on the RAS(ON) Inhibitors
08 Apr 2024 //
GLOBENEWSWIRE
Aethon Collab with Revolution Med to Discover Novel Aethon Antibody Programs
04 Apr 2024 //
PR NEWSWIRE
Revolution Medicines to Participate in Upcoming Investor Conferences
04 Apr 2024 //
GLOBENEWSWIRE
Revolution to Deliver Multiple Presentations at the Annual Meeting 2024
28 Mar 2024 //
GLOBENEWSWIRE
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Revolution Medicines to Report Results for Fourth Quarter and Full Year 2023
20 Feb 2024 //
GLOBENEWSWIRE
Revolution Medicines to Participate in Upcoming Investor Conferences
01 Feb 2024 //
GLOBENEWSWIRE
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
GLOBENEWSWIRE
Revolution Medicines Completes Acquisition of EQRx
09 Nov 2023 //
GLOBENEWSWIRE
Revolution Medicines Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
ISS Recommend Revolution Medicines Stockholders Vote FOR Acquisition of EQRx
01 Nov 2023 //
GLOBENEWSWIRE
Revolution Medicines to Report Financial Results for Third Quarter 2023
31 Oct 2023 //
GLOBENEWSWIRE
Why Revolution Medicines Stock Is Crashing Today
23 Oct 2023 //
FOOL
Revolution Medicines Presents Data from Phase 1/1b Trial of RMC-6236
22 Oct 2023 //
GLOBENEWSWIRE
COO Margaret Horn sells 25,000 shares of Revolution Medicines
19 Oct 2023 //
SEEKING ALPHA
Why Shares of Revolution Medicines Were Popping on Friday
13 Oct 2023 //
FOOL
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236
13 Oct 2023 //
GLOBENEWSWIRE
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences
04 Oct 2023 //
GLOBENEWSWIRE
Revolution Medicines Doses First Patient in Phase 1/1b Trial of RMC-9805
19 Sep 2023 //
GLOBENEWSWIRE
Revolution Medicines Announces Publication of Tri-Complex Inhibitor
17 Aug 2023 //
GLOBENEWSWIRE
Revolution Medicines Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PRESS RELEASE
Revolution Medicines to Report Financial Results for Second Quarter 2023
03 Aug 2023 //
GLOBENEWSWIRE
Revolution Medicines, Inc. to Acquire EQRx, Inc.
01 Aug 2023 //
GLOBENEWSWIRE
Revolution Medicines to Participate in Upcoming Investor Conferences
08 Jun 2023 //
PRESS RELEASE
Revolution to Participate in TD Cowen 4th Annual Oncology Innovation Summit
24 May 2023 //
GLOBENEWSWIRE
Revolution Medicines Reports 1Q 2023 FYR and Update on Corporate Progress
08 May 2023 //
GLOBENEWSWIRE
Revolution Medicines to Report Financial Results for First Quarter 2023
01 May 2023 //
GLOBENEWSWIRE
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
13 Apr 2023 //
GLOBENEWSWIRE
Revolution Medicines to Present Preclinical Data at the Annual Meeting 2023
06 Apr 2023 //
GLOBENEWSWIRE
Revolution Medicines Announces Closing of Public Offering of Common Stock
07 Mar 2023 //
GLOBENEWSWIRE
Revolution Announces Pricing of $300.0 Million Public Offering of Common Stock
02 Mar 2023 //
GLOBENEWSWIRE
Revolution Medicines Announces Commencement of Public Offering of Common Stock
01 Mar 2023 //
GLOBENEWSWIRE
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Revolution Medicines to Report Financial Results for Fourth Quarter 2022
21 Feb 2023 //
GLOBENEWSWIRE
Revolution Medicines to Participate in Upcoming Investor Conferences
02 Feb 2023 //
GLOBENEWSWIRE
Strength Seen in Revolution: Can Its 15.9% Jump Turn into More Strength?
13 Jan 2023 //
NASDAQ
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
Revolution Announces Publication Describing Design and Synthesis of RMC-5552
19 Dec 2022 //
GLOBENEWSWIRE
Sanofi Terminated the Collaboration with Revolution Medicines
08 Dec 2022 //
GLOBENEWSWIRE
Revolution Medicines to Participate in Upcoming Investor Conferences
09 Nov 2022 //
PRESS RELEASE
Revolution Medicines Reports 3Q 2022 Financial Results and Update
07 Nov 2022 //
GLOBENEWSWIRE
Revolution Medicines to Report Financial Results for Third Quarter 2022
01 Nov 2022 //
GLOBENEWSWIRE
Revolution Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291
22 Sep 2022 //
GLOBENEWSWIRE
Revolution Medicines Strengthens Senior Management Team with Promotions
01 Sep 2022 //
GLOBENEWSWIRE
Revolution Medicines to Participate in Upcoming Investor Conferences
31 Aug 2022 //
PRESS RELEASE
